RGX-121

GENETIC2 trials

Sponsors

REGENXBIO Inc.

Conditions

Mucopolysaccharidosis Type II (MPS II)

Phase 1

RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

CompletedNCT04571970

REGENXBIO Inc.Mucopolysaccharidosis Type II (MPS II)

Start: 2021-03-11End: 2024-05-23Updated: 2025-01-28

Phase 2

CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)

Active, not recruitingNCT03566043

REGENXBIO Inc.Mucopolysaccharidosis Type II (MPS II)

Start: 2018-09-27End: 2025-08-31Target: 48Updated: 2025-01-28